Restore Mind Medicine
The Not So "Refreshed Board"
September 27, 2022
MindMed announces the
destructive September financing.
Leading to 47% drop over night.
CEO Barrow
Chair Carol Vallone
Vice Chair Krebs
Director Crystal
Director Makes
Executive President
Wernli
January - December 2021
MindMed administers high doses of
MM-110 to patients, beyond what
the FDA believed was safe.
2021
2022
SEP OCT NOV DEC JAN
I
SEP
2021
I
August 11, 2022
MindMed announces the termination
of the MM-110 program.
Director September 2021 to Present
FEB MAR APR MAY JUN JUL
Director September 2021 to Present
OCT NOV
CEO/CDO January 2021 to Present
Director February 2020 to Present
Source: Company SEC Filings, Company SEDAR Filings,
MindMed Press Releases.
Director February 2020 to August 2022
DEC
I
JAN FEB MAR APR
2022
MAY
May 17, 2022
MindMed announces that
MM-110 is safe and tolerable.
AUG
JUN
SEP
I
Director December 2021 to Present
I
I
I
I
ост
1
Executive President August 2020 to Present
I
I
'
'
I
2023
NOV DEC JAN
JUL AUG SEPI OCT
I
1
I
|
I
I
I
1
I
I
1
I
INOV
I
I
I
I
I
I
DEC
JAN
2023
FEB
September - October 31, 2022
FCM pens multiple letters to the board demanding
the Board hold executives accountable.
MAR
May 1, 2023
MindMed announces poorly
designed, rubberstamped
compensation program
which provided executives
credit for failed items.
Director August to 2022
APR MAY JUN
FEB MAR APR MAY JUN
November 9, 2022
MindMed changes executive employment
agreements to include golden parachutes.
11View entire presentation